Amicrobe's priority is the prevention and treatment of life-threatening infections.
Amicidins are a new class of antimicrobials designed for direct application to tissues, especially the exposed tissues of surgery and trauma. Based on A-Blocks technology, Amicidins are long-chain amino acid block copolymers that are broadly antimicrobial against gram-positive and gram-negative bacteria (including antibiotic-resistant strains), as well as yeast. These novel biological therapeutics also bring beneficial physical properties and a high level of safety.
Amicidin-α Surgical Gel and Amicidin-β Solution, are intended to prevent and treat the life threatening infections of surgery and trauma.*
This work is supported by US Army Medical Research & Materiel Command through the Military Burn Research Program under Award No. W81XWH-15-2-0065 and DoD2 by the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Medical Research Program under Award No. W81XWH-16-1-0561. Opinions, interpretations, conclusions and recommendations are those of Amicrobe and are not necessarily endorsed by the Department of Defense. CARB-X support is provided by the Department of Health & Human Services Asst. Secretary for Preparedness & Response (BARDA) and Wellcome Trust through Boston University subaward 4500002454.
Amicidin-α Surgical Gel
Amicidin-α Surgical Gel is intended primarily for prophylaxis against infection in surgery & trauma.
Designed as a "sword and shield," Amicidin-α kills microbes directly and forms an active microbial barrier to prevent further contamination. Amicidin-α forms a deformable ("flowable") hydrogel that can pass through small openings and rapidly re-gel. This property should facilitate entry into tissue recesses, as well as delivery through applicators such as needles, catheters and spray nozzles.
Amicidin-α Surgical Gel is in late-stage preclinical development.* Working with surgical and medical colleagues, Amicrobe is designing clinical trials and preparing for meetings with regulatory authorities.
Amicidin-β Solution is intended primarily for treatment of life-threatening infections.
Amicidin-β demonstrates potent, direct microbial killing and enhanced anti-biofilm properties. Amicidin-β possesses surfactant activity that can assist with tissue cleansing and debridement. It will be applied directly to heavily contaminated or overtly infected tissues, including those with foreign bodies and/or established biofilms.
Amicidin-β Solution is in late-stage preclinical development.* Working with surgical and medical colleagues, Amicrobe is designing clinical trials and preparing for meetings with regulatory authorities.